Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine in Refractory/Relapsed MDS, AML, and CMML
NCT02197676Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Aug 2014
- Primary completion
- Feb 2016
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of guadecitabine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Started Aug 2014; status: completed.
02
Drugs
guadecitabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02197676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197676.